The EU to Purchase 200 Million COVID-19 Vaccines From J&J

New Jersey-based Johnson & Johnson announced on October 8, 2020, the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Purchase Agreement in which the Janssen Pharmaceutical Companies will supply 200 million doses of its COVID-19 vaccine candidate to EU Member States following approval or authorization from regulators.

According to this press statement, the EC has an option to purchase an additional 200 million vaccine doses of Ad26.COV2-S (JNJ-78436735).